Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$156 Mln
Revenue (TTM)
$84 Mln
Net Profit (TTM)
$0 Mln
ROE
-11.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
20.1
Industry P/E
--
EV/EBITDA
74.6
Div. Yield
0 %
Debt to Equity
-1.4
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
45,980,019
CFO
$-49.95 Mln
EBITDA
$-64.11 Mln
Net Profit
$-164.66 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
| 87.3 | 4.6 | 47.4 | 180.2 | -29.0 | -17.9 | -5.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
| -54.1 | -71.0 | 21.2 | -24.2 | -45.9 | 6.4 | 175.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
3.4 | 155.9 | 84.4 | -9.2 | 0.2 | -- | -- | 20.1 |
| 4.5 | 840.6 | 14.1 | -33.5 | -264.9 | -38.5 | -- | 10.6 | |
| 5.4 | 1,986.2 | 10,309.0 | 155.3 | 17.0 | -17 | 12.7 | 18.8 | |
| 2.5 | 938.5 | 193.4 | -9.5 | -8.9 | -0.9 | -- | 0.8 | |
| 4.0 | 18.2 | 0.0 | -26.6 | -- | -289.6 | -- | 1.0 | |
| 4.0 | 18.2 | 0.0 | -26.6 | -- | -289.6 | -- | 1.0 |
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess... abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada. As of September 25, 2025, Theratechnologies Inc. operates as a subsidiary of CB Biotechnology, LLC. Read more
President, CEO & Director
Mr. Paul Lévesque
President, CEO & Director
Mr. Paul Lévesque
Headquarters
Montreal, QC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Theratechnologies Inc (THTX) is $3.39 (NASDAQ) as of 02-Oct-2025 09:30 EDT. Theratechnologies Inc (THTX) has given a return of -29.02% in the last 3 years.
Since, TTM earnings of Theratechnologies Inc (THTX) is negative, P/E ratio is not available.
The P/B ratio of Theratechnologies Inc (THTX) is 20.13 times as on 02-Oct-2025, a 90 premium to its peers’ median range of 10.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Theratechnologies Inc (THTX) are Rs 3.40 and Rs 1.12 as of 05-Apr-2026.
Theratechnologies Inc (THTX) has a market capitalisation of $ 156 Mln as on 02-Oct-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Theratechnologies Inc (THTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.